Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Opposition mounts to genetic modification of human embryos

A group of U.S. scientists and activists on Monday called for a global ban on the use of new tools to edit the genes of human embryos, in a report issued a day before a major international meeting in Washington to discuss the ethical and policy issues surrounding the technology.   A technological innovation that […]

Read More »

Exercise as young adult tied to heart health decades later

(Reuters Health) – Young adults who exercise may have a lower risk of cardiovascular disease and higher survival odds decades later than their peers who aren’t as active early in life, a U.S. study suggests. Fitness has long been linked to a reduced risk of heart disease in older adults. The new study, however, offers […]

Read More »

New York is first U.S. city with salt warning on restaurant menus

A tiny salt shaker symbol that warns certain meals are high in sodium will appear, starting Tuesday, on menus in chain restaurants in New York City, the first U.S. city to take the step in an effort to combat heart disease and stroke. Any menu item containing more than 2,300 milligrams (0.08 oz) of sodium, […]

Read More »

FDA approves new Bristol-Myers treatment for multiple myeloma

The U.S. Food and Drug Administration said on Monday it had approved a drug to be sold by Bristol-Myers Squibb Co as a treatment for a form of blood cancer. The FDA said it approved the treatment, Empliciti, to be used in multiple myeloma patients in combination with Celgene Corp’s Revlimid and common anti-inflammatory drug […]

Read More »

Supreme Court rejects Covidien bid to restore patent verdict against Ethicon

The U.S. Supreme Court on Monday rejected an appeal by Covidien LP seeking to restore a $176 million patent infringement verdict against Johnson & Johnson subsidiary Ethicon Inc.   In refusing to hear the case, the high court left in place a December 2014 ruling by the U.S. Court of Appeals for the Federal Circuit […]

Read More »

Servier Slashes 610 Jobs in Company Reorganization

SURESNES, France– Privately-held Servier, a French pharmaceutical company, will slash 610 employees as it faces increased competition and a tougher regulatory environment, Reuters reported Friday.   Reuters said the firm, which employs approximately 21,000 worldwide, said it has faced financial losses due to the end of patents, competition from generic drugs, regulated price controls, increased […]

Read More »

Beijing aims to refill medicine chest with Made in China drugs

China, already a global powerhouse in high-tech areas from solar panels to bullet trains, is turning its industrial might to the challenge of making more of its own drugs for a vast and aging population.   Given the 10 years or more it typically takes to bring a new medicine to market, original “Made in […]

Read More »

Heptares Enters Strategic Drug Discovery Collaboration With Pfizer Focused On GPCR Targets Across Multiple Therapeutic Areas

LONDON and BOSTON, November 30, 2015 /PRNewswire/ — Heptares Therapeutics (“Heptares”), the clinical-stage GPCR structure-guided drug discovery and development company and wholly-owned subsidiary of Sosei Group Corporation (“Sosei”; TSE Mothers Index: 4565), announces that it has entered into a strategic drug discovery collaboration with Pfizer Inc. (NYSE: PFE) to research and develop potential new medicines […]

Read More »

Pfizer Inks $1.89 Billion Discovery Deal with Heptares, Takes $33 Million Stake in Sosei

Sosei Subsidiary Heptares Enters Strategic Drug Discovery Collaboration with Pfizer Inc. Focused on GPCR Targets Across Multiple Therapeutic Areas TOKYO–(BUSINESS WIRE)–Sosei Group Corporation (“Sosei”) (TOKYO:4565) today announces that its wholly-owned subsidiary, Heptares Therapeutics has entered into a strategic drug discovery collaboration with Pfizer Inc. (NYSE: PFE) to research and develop potential new medicines directed at […]

Read More »

Roche pulls out of superbug antibiotic project

Swiss drugmaker Roche Holding has dropped out of a high-profile project to develop an antibiotic for treating “superbug” infections, the company said on Sunday.   Roche had agreed in 2013 to pay privately held partner Polyphor up to 500 million Swiss francs ($485.3 million) for rights to the product, marking a rare foray by a […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2018 Focus: Top 50 Pharma, Company of the Year and more!

Subscribe

Ad Right Bottom